BELGRADE, Mont., Oct. 22 /PRNewswire/ -- Bacterin International Holdings, Inc. (OTC Bulletin Board: BIHI) (“Bacterin”), today announced that it is scheduled to present at the upcoming Singular Research 5th Annual Best of the Uncovereds conference on Thursday, November 4, 2010 at 3:20p.m.(PT) at the Luxe Hotel Sunset Boulevard, Los Angeles, California.
Guy Cook, Founder & CEO of Bacterin, and John Gandolfo, Bacterin’s chief financial officer, will review and provide an update on the Company’s progress. Bacterin, founded in 1998 as a spin out from the National Science Foundation’s Center for Biofilm Engineering, is a developer of unique, anti-infective coatings for medical applications and a producer of revolutionary scaffolds for tissue regeneration.
About Bacterin International Holdings, Inc.
Bacterin International Holdings, Inc. (“Bacterin”) develops, manufactures and markets biologics products to domestic and international markets. Bacterin’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain by facet joint stabilization, promotion of bone fusion in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral bone defect repair in articulating joint surgeries.
Bacterin’s Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin’s strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination on medical devices drug delivery, local (as opposed to systemic) pain management, and anti-thrombotic factors for medical device applications.
Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art, fully compliant and FDA registered facility, equipped with four “Class 100" clean rooms. For further information please visit www.bacterin.com.
About Singular Research
Singular Research aims to be the most trusted supplier of independent research on small-cap companies.
* Our analysts research companies generally that are not covered by any other firms.
* We provide Honest Advice: Our Independent analysts have no financial interest in the stocks we cover. Analysts are compensated based on the accuracy of their research calls not through trading commissions or investment banking fees.
* Track Record: Our coverage list compounded annual performance since inception is 13.04% vs. 3.45% for the Russell 2000, from August 2004 through September 2010. Performance YTD in 2010 is 8.9% vs. 7.4% for the Russell 2000.
http://www.singular-research.com/discover/broadcast-news.htm
This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors are detailed from time to time in Bacterin’s filings with the United States Securities and Exchange Commission and other regulatory authorities.
SOURCE Bacterin International Holdings, Inc.
